Notice Number: NOT-HL-18-661
Key Dates
Release Date: October 31, 2018
PAR-18-714
Issued by
National Heart, Lung, and Blood Institute (NHLBI)
Purpose
The purpose of this Notice is to inform potential applicants that the National Heart, Lung and Blood Institute (NHLBI) will participate, effective immediately, in PAR-18-714 Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15-Clinical Trial Not Allowed).
The following sections of PAR-18-714 have been modified (shown in italics).:
Part 1. Overview Information Components of Participating Organizations
National Institute of General Medical Sciences (NIGMS )
National Institute of Dental and Craniofacial Research (NIDCR)
National Human Genome Research Institute (NHGRI )
National Institute of Allergy and Infectious Diseases (NIAID)
National Library of Medicine (NLM)
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.859, 93.121, 93.859, 93.121, 93.172; 93.855; 93.879; 93.393; 93.394; 93.395; 93.396; 93.399; 93.837; 93.838; 93.839; 93.940; 93.233
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Part 2. Section I. Funding Opportunity Description
National Heart, Lung, and Blood Institute (NHLBI) http://www.nhlbi.nih.gov/index.htm
The NHLBI supports basic and clinical research pertaining to the structure, function, and diseases of the cardiovascular system, lungs, blood and blood vessels, and sleep disorders. The NHLBI also supports research in stem cell biology and transplantation, transfusion medicine, and blood resources.
The NHLBI carries out its mission through a number of research programs that provide support for projects ranging from studies at the molecular level to whole body studies in man and animals. Examples of research areas supported by the NHLBI include atherosclerosis, hypertension, cerebrovascular disease (directed at the dependent variable of blood, heart, or blood vessel), coronary heart disease, peripheral vascular diseases, arrhythmias, heart failure, and shock, congenital and rheumatic heart diseases, cardiomyopathies and infections of the heart, circulatory assistance, lung cell and molecular biology, chronic obstructive lung diseases, pediatric pulmonary diseases, cystic fibrosis, sleep-disordered breathing, asthma, fibrotic and immunologic lung diseases, acute respiratory failure, pulmonary vascular diseases, HIV-associated lung disorders and bone marrow suppression, bleeding and clotting disorders, disorders of the red blood cell such as sickle cell disease and Cooley's anemia, bone marrow failure syndromes, and blood resources.
Section VII. Agency Contacts
Scientific/Research Contact(s)
Aaron Laposky, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-7837
Email: [email protected]
Financial/Grants Management Contact(s)
Ryan Lombardi, MS
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8042
Email: [email protected]
All other aspects of this FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Aaron Laposky, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-7837
Email: [email protected]
and Human Services (HHS)
